
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News / Product</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Fri, 28 Nov 2008 00:05:23 EET</pubDate>
<language>en</language>
<item>
<title><![CDATA[Pfizer's Novel HIV/AIDS Treatment SELZENTRY]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY%C2%99/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY%C2%99/</comments>
<pubDate>Fri, 28 Nov 2008 00:05:23 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizers_Novel_HIVAIDS_Treatment_SELZENTRY%C2%99/</guid>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other ant<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sandoz receives positive EU opinion for biosimilar filgrastim]]></title>
<link>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</link>
<comments>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</comments>
<pubDate>Thu, 27 Nov 2008 00:04:31 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Sandoz_receives_positive_EU_opinion_for_biosimilar_filgrastim/</guid>
<description><![CDATA[Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biop<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[METTLER TOLEDO SAFELINE Introduces the Tablex 2 for Detection of Metal Contaminants in the Tableting Room]]></title>
<link>http://www.worldpharmanews.net/Product/METTLER_TOLEDO_SAFELINE_Introduces_the_Tablex_2_for_Detection_of_Metal_Contaminants_in_the_Tableting_Room/</link>
<comments>http://www.worldpharmanews.net/Product/METTLER_TOLEDO_SAFELINE_Introduces_the_Tablex_2_for_Detection_of_Metal_Contaminants_in_the_Tableting_Room/</comments>
<pubDate>Wed, 26 Nov 2008 00:12:22 EET</pubDate>
<dc:creator>fdibartolo</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/METTLER_TOLEDO_SAFELINE_Introduces_the_Tablex_2_for_Detection_of_Metal_Contaminants_in_the_Tableting_Room/</guid>
<description><![CDATA[November 24, 2008 -- Mettler-Toledo Safeline, the worldwide leader in metal detection and x-ray inspection equipment, presents the Tablex 2 metal detector to safeguard pharmaceutical and nutraceutica<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)]]></title>
<link>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</link>
<comments>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</comments>
<pubDate>Sat, 22 Nov 2008 11:08:16 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/EMEA_recommends_the_suspension_of_the_marketing_authorisation_of_Ionsys_fentanyl_hydrochloride/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride), from Janssen-Cilag International NV, because of a defect with th<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer withdraws its application to change the marketing authorisation for Viagra]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</comments>
<pubDate>Sat, 22 Nov 2008 11:08:04 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_withdraws_its_application_to_change_the_marketing_authorisation_for_Viagra/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has been formally notified by Pfizer Limited of its decision to withdraw its application for a change to the marketing authorisation for the medicine Viagra (sild<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants]]></title>
<link>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</link>
<comments>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</comments>
<pubDate>Thu, 20 Nov 2008 00:04:47 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Russia_Chooses_Inactivated_Polio_Vaccine_from_Sanofi_Pasteur_for_Primary_Immunization_of_All_Infants/</guid>
<description><![CDATA[Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Russia has chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for primary immunization of all infants. The IPV do<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[SEROQUEL XR and SEROQUEL Approved in Europe for New Indications]]></title>
<link>http://www.worldpharmanews.net/Product/SEROQUEL_XR_and_SEROQUEL_Approved_in_Europe_for_New_Indications/</link>
<comments>http://www.worldpharmanews.net/Product/SEROQUEL_XR_and_SEROQUEL_Approved_in_Europe_for_New_Indications/</comments>
<pubDate>Sat, 15 Nov 2008 11:04:30 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/SEROQUEL_XR_and_SEROQUEL_Approved_in_Europe_for_New_Indications/</guid>
<description><![CDATA[AstraZeneca has announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Re<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Seizes Contaminated Heparin from a Cincinnati Manufacturer]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Seizes_Contaminated_Heparin_from_a_Cincinnati_Manufacturer/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Seizes_Contaminated_Heparin_from_a_Cincinnati_Manufacturer/</comments>
<pubDate>Sun, 09 Nov 2008 09:41:21 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Seizes_Contaminated_Heparin_from_a_Cincinnati_Manufacturer/</guid>
<description><![CDATA[As part of the U.S. Food and Drug Administration's ongoing efforts to ensure that heparin for patients remains safe, the government has seized 11 lots of heparin from Celsus Laboratories Inc. in Cin<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Industry solution for pharmaceutical companies (.pdf)]]></title>
<link>http://www.worldpharmanews.net/Product/Industry_solution_for_pharmaceutical_companies_-pdf/</link>
<comments>http://www.worldpharmanews.net/Product/Industry_solution_for_pharmaceutical_companies_-pdf/</comments>
<pubDate>Tue, 04 Nov 2008 00:12:23 EET</pubDate>
<dc:creator>ariadne</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Industry_solution_for_pharmaceutical_companies_-pdf/</guid>
<description><![CDATA[The European Commission, organisations, associations and pharmaceutical companies all agree on the fact that a uniform solution for the security and traceability of medicinal products needs to be fou<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Issues Warning Letters to Bayer HealthCare for Illegally Marketing Two Unapproved Drugs]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Issues_Warning_Letters_to_Bayer_HealthCare_for_Illegally_Marketing_Two_Unapproved_Drugs/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Issues_Warning_Letters_to_Bayer_HealthCare_for_Illegally_Marketing_Two_Unapproved_Drugs/</comments>
<pubDate>Fri, 31 Oct 2008 00:05:55 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Issues_Warning_Letters_to_Bayer_HealthCare_for_Illegally_Marketing_Two_Unapproved_Drugs/</guid>
<description><![CDATA[The U.S. Food and Drug Administration today sent Warning Letters to Bayer HealthCare concerning two unlawful, over-the-counter (OTC) aspirin products - Bayer Women's Low Dose Aspirin + Calcium (Baye<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia]]></title>
<link>http://www.worldpharmanews.net/Product/European_CHMP_adopts_negative_opinion_on_Cymbalta_for_the_treatment_of_fibromyalgia/</link>
<comments>http://www.worldpharmanews.net/Product/European_CHMP_adopts_negative_opinion_on_Cymbalta_for_the_treatment_of_fibromyalgia/</comments>
<pubDate>Tue, 28 Oct 2008 00:14:27 EET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_CHMP_adopts_negative_opinion_on_Cymbalta_for_the_treatment_of_fibromyalgia/</guid>
<description><![CDATA[The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta® (duloxetine hydrochloride) application for the treatmen<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[EMEA recommends suspension of the marketing authorisation of Acomplia]]></title>
<link>http://www.worldpharmanews.net/Product/EMEA_recommends_suspension_of_the_marketing_authorisation_of_Acomplia/</link>
<comments>http://www.worldpharmanews.net/Product/EMEA_recommends_suspension_of_the_marketing_authorisation_of_Acomplia/</comments>
<pubDate>Sun, 26 Oct 2008 02:28:08 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/EMEA_recommends_suspension_of_the_marketing_authorisation_of_Acomplia/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Acomplia (rimonabant) from Sanofi-Aventis. The EMEA's Committee for Medicinal Products for Huma<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Announces European SEROQUEL XR Submission]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_Announces_European_SEROQUEL_XR_Submission/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_Announces_European_SEROQUEL_XR_Submission/</comments>
<pubDate>Wed, 22 Oct 2008 19:00:45 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_Announces_European_SEROQUEL_XR_Submission/</guid>
<description><![CDATA[AstraZeneca has announced its submission of SEROQUEL XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatmen<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK responds to NICE's second technology appraisal consultation document on the use of Tyverb]]></title>
<link>http://www.worldpharmanews.net/Product/GSK_responds_to_NICEs_second_technology_appraisal_consultation_document_on_the_use_of_Tyverb/</link>
<comments>http://www.worldpharmanews.net/Product/GSK_responds_to_NICEs_second_technology_appraisal_consultation_document_on_the_use_of_Tyverb/</comments>
<pubDate>Thu, 16 Oct 2008 00:02:10 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GSK_responds_to_NICEs_second_technology_appraisal_consultation_document_on_the_use_of_Tyverb/</guid>
<description><![CDATA[The draft recommendations announced yesterday by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Medicines Agency recommends update of product information of Tysabri]]></title>
<link>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_update_of_product_information_of_Tysabri/</link>
<comments>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_update_of_product_information_of_Tysabri/</comments>
<pubDate>Fri, 26 Sep 2008 12:10:26 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_update_of_product_information_of_Tysabri/</guid>
<description><![CDATA[The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the product information for Tysabri (natalizumab) be updated to further increase awareness <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_Expanded_Uses_for_Gardasil_to_Include_Preventing_Certain_Vulvar_and_Vaginal_Cancers/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_Expanded_Uses_for_Gardasil_to_Include_Preventing_Certain_Vulvar_and_Vaginal_Cancers/</comments>
<pubDate>Tue, 16 Sep 2008 01:17:00 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_Expanded_Uses_for_Gardasil_to_Include_Preventing_Certain_Vulvar_and_Vaginal_Cancers/</guid>
<description><![CDATA[The U.S. Food and Drug Administration announced the approval of the vaccine Gardasil for the prevention of vaginal and vulvar cancer caused by Human Papillomavirus (HPV) types 16 and 18 in girls and <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_Will_Withdraw_Global_Marketing_Applications_for_Dalbavancin_to_Conduct_a_New_Trial/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_Will_Withdraw_Global_Marketing_Applications_for_Dalbavancin_to_Conduct_a_New_Trial/</comments>
<pubDate>Thu, 11 Sep 2008 09:47:59 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_Will_Withdraw_Global_Marketing_Applications_for_Dalbavancin_to_Conduct_a_New_Trial/</guid>
<description><![CDATA[Pfizer Inc announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug applic<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New low-dose oral contraceptive YAZ launched in Europe]]></title>
<link>http://www.worldpharmanews.net/Product/New_low-dose_oral_contraceptive_YAZ%AE_launched_in_Europe/</link>
<comments>http://www.worldpharmanews.net/Product/New_low-dose_oral_contraceptive_YAZ%AE_launched_in_Europe/</comments>
<pubDate>Wed, 10 Sep 2008 11:31:23 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/New_low-dose_oral_contraceptive_YAZ%AE_launched_in_Europe/</guid>
<description><![CDATA[Bayer Schering Pharma's YAZ® will be available across Europe as of September 2008. YAZ® is the first oral contraceptive containing 3 mg of the unique progestin drospirenone combined with 0.02 mg of <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk launches a next generation of FlexPen]]></title>
<link>http://www.worldpharmanews.net/Product/Novo_Nordisk_launches_a_next_generation_of_FlexPen%AE/</link>
<comments>http://www.worldpharmanews.net/Product/Novo_Nordisk_launches_a_next_generation_of_FlexPen%AE/</comments>
<pubDate>Wed, 10 Sep 2008 11:30:28 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Novo_Nordisk_launches_a_next_generation_of_FlexPen%AE/</guid>
<description><![CDATA[Novo Nordisk announced the launch of a next generation of FlexPen® at the European Association for the Study of Diabetes (EASD) Annual Meeting. The new insulin injection device builds upon the high s<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon]]></title>
<link>http://www.worldpharmanews.net/Product/Pfizer_and_Medivation_Enter_into_Global_Agreement_to_Co-Develop_and_Market_Dimebon/</link>
<comments>http://www.worldpharmanews.net/Product/Pfizer_and_Medivation_Enter_into_Global_Agreement_to_Co-Develop_and_Market_Dimebon/</comments>
<pubDate>Fri, 05 Sep 2008 10:44:59 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Pfizer_and_Medivation_Enter_into_Global_Agreement_to_Co-Develop_and_Market_Dimebon/</guid>
<description><![CDATA[Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis decides not to pursue further development of Aurograb(TM)]]></title>
<link>http://www.worldpharmanews.net/Product/Novartis_decides_not_to_pursue_further_development_of_AurograbTM/</link>
<comments>http://www.worldpharmanews.net/Product/Novartis_decides_not_to_pursue_further_development_of_AurograbTM/</comments>
<pubDate>Wed, 03 Sep 2008 01:14:05 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Novartis_decides_not_to_pursue_further_development_of_AurograbTM/</guid>
<description><![CDATA[Novartis has decided not to pursue further development of the pharmaceuticals pipeline project Aurograb(TM), an add-on therapy to antibiotics that was being assessed for use in treating deep-seated s<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</comments>
<pubDate>Mon, 25 Aug 2008 01:14:56 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</guid>
<description><![CDATA[The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</comments>
<pubDate>Fri, 15 Aug 2008 01:15:34 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</guid>
<description><![CDATA[AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke]]></title>
<link>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</link>
<comments>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</comments>
<pubDate>Fri, 08 Aug 2008 09:24:14 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</guid>
<description><![CDATA[Pfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular eve<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis]]></title>
<link>http://www.worldpharmanews.net/Product/First_interleukin-6_inhibitor_IL-6_to_offer_new_therapeutic_option_for_rheumatoid_arthritis/</link>
<comments>http://www.worldpharmanews.net/Product/First_interleukin-6_inhibitor_IL-6_to_offer_new_therapeutic_option_for_rheumatoid_arthritis/</comments>
<pubDate>Fri, 01 Aug 2008 01:48:03 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/First_interleukin-6_inhibitor_IL-6_to_offer_new_therapeutic_option_for_rheumatoid_arthritis/</guid>
<description><![CDATA[Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nexavar Approved for Treatment of Liver Cancer in China]]></title>
<link>http://www.worldpharmanews.net/Product/Nexavar_Approved_for_Treatment_of_Liver_Cancer_in_China/</link>
<comments>http://www.worldpharmanews.net/Product/Nexavar_Approved_for_Treatment_of_Liver_Cancer_in_China/</comments>
<pubDate>Tue, 29 Jul 2008 01:13:37 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Nexavar_Approved_for_Treatment_of_Liver_Cancer_in_China/</guid>
<description><![CDATA[Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar® (sorafenib) tablets for the treatment<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines]]></title>
<link>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_restricting_the_use_of_oral_moxifloxacin-containing_medicines/</link>
<comments>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_restricting_the_use_of_oral_moxifloxacin-containing_medicines/</comments>
<pubDate>Mon, 28 Jul 2008 10:49:05 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Medicines_Agency_recommends_restricting_the_use_of_oral_moxifloxacin-containing_medicines/</guid>
<description><![CDATA[Finalising a review of the safety of moxifloxacin-containing medicines for oral use, the European Medicines Agency (EMEA) has concluded that these medicines should only be prescribed in the treatment<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nexavar Study Demonstrates Significant Improvement in Overall Survival]]></title>
<link>http://www.worldpharmanews.net/Product/Nexavar_Study_Demonstrates_Significant_Improvement_in_Overall_Survival/</link>
<comments>http://www.worldpharmanews.net/Product/Nexavar_Study_Demonstrates_Significant_Improvement_in_Overall_Survival/</comments>
<pubDate>Sun, 27 Jul 2008 10:07:38 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Nexavar_Study_Demonstrates_Significant_Improvement_in_Overall_Survival/</guid>
<description><![CDATA[Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of Medicine published landmark results of a Nexavar study in liver cancer. The data of the Phase III trial sh<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows]]></title>
<link>http://www.worldpharmanews.net/Product/Patients_More_Likely_to_Stay_on_Lipitor_Than_Simvastatin_a_Large_Observational_Study_Shows/</link>
<comments>http://www.worldpharmanews.net/Product/Patients_More_Likely_to_Stay_on_Lipitor_Than_Simvastatin_a_Large_Observational_Study_Shows/</comments>
<pubDate>Wed, 09 Jul 2008 01:10:28 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Patients_More_Likely_to_Stay_on_Lipitor_Than_Simvastatin_a_Large_Observational_Study_Shows/</guid>
<description><![CDATA[Pfizer announced that new statin users who took Lipitor® (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an obse<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline responds to FDA on Cervarix and plans to submit final study data for approval]]></title>
<link>http://www.worldpharmanews.net/Product/GlaxoSmithKline_responds_to_FDA_on_Cervarix%AE_and_plans_to_submit_final_study_data_for_approval/</link>
<comments>http://www.worldpharmanews.net/Product/GlaxoSmithKline_responds_to_FDA_on_Cervarix%AE_and_plans_to_submit_final_study_data_for_approval/</comments>
<pubDate>Thu, 03 Jul 2008 13:34:09 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GlaxoSmithKline_responds_to_FDA_on_Cervarix%AE_and_plans_to_submit_final_study_data_for_approval/</guid>
<description><![CDATA[GlaxoSmithKline provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of Cervarix®, its vaccine to prevent cervical cancer.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Cervarix, GSK's cervical cancer vaccine, wins tender for UK national immunisation programme]]></title>
<link>http://www.worldpharmanews.net/Product/Cervarix%C2%99_GSKs_cervical_cancer_vaccine_wins_tender_for_UK_national_immunisation_programme/</link>
<comments>http://www.worldpharmanews.net/Product/Cervarix%C2%99_GSKs_cervical_cancer_vaccine_wins_tender_for_UK_national_immunisation_programme/</comments>
<pubDate>Mon, 23 Jun 2008 01:42:14 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Cervarix%C2%99_GSKs_cervical_cancer_vaccine_wins_tender_for_UK_national_immunisation_programme/</guid>
<description><![CDATA[GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme. Th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Files Applications for Approval of Mozobil in the United States and Europe]]></title>
<link>http://www.worldpharmanews.net/Product/Genzyme_Files_Applications_for_Approval_of_Mozobil_in_the_United_States_and_Europe/</link>
<comments>http://www.worldpharmanews.net/Product/Genzyme_Files_Applications_for_Approval_of_Mozobil_in_the_United_States_and_Europe/</comments>
<pubDate>Fri, 20 Jun 2008 11:37:06 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Genzyme_Files_Applications_for_Approval_of_Mozobil_in_the_United_States_and_Europe/</guid>
<description><![CDATA[Genzyme Corporation (Nasdaq: GENZ) announced that it has submitted marketing applications in both the United States and the European Union for Mozobil™ (plerixafor), a product candidate intended to e<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Romiplostim Data Show Potential Long-Term Efficacy and Safety]]></title>
<link>http://www.worldpharmanews.net/Product/Romiplostim_Data_Show_Potential_Long-Term_Efficacy_and_Safety/</link>
<comments>http://www.worldpharmanews.net/Product/Romiplostim_Data_Show_Potential_Long-Term_Efficacy_and_Safety/</comments>
<pubDate>Wed, 18 Jun 2008 14:08:18 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Romiplostim_Data_Show_Potential_Long-Term_Efficacy_and_Safety/</guid>
<description><![CDATA[Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytop<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First positive health technology assessments for novel oral anticoagulant Pradaxa]]></title>
<link>http://www.worldpharmanews.net/Product/First_positive_health_technology_assessments_for_novel_oral_anticoagulant_Pradaxa%AE/</link>
<comments>http://www.worldpharmanews.net/Product/First_positive_health_technology_assessments_for_novel_oral_anticoagulant_Pradaxa%AE/</comments>
<pubDate>Wed, 11 Jun 2008 07:33:39 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/First_positive_health_technology_assessments_for_novel_oral_anticoagulant_Pradaxa%AE/</guid>
<description><![CDATA[The Scottish Medicines Consortium (SMC) has accepted Pradaxa® (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the pr<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for DuoCover]]></title>
<link>http://www.worldpharmanews.net/Product/Bristol-Myers_Squibb_Pharma_EEIG_withdraws_its_marketing_authorisation_application_for_DuoCover/</link>
<comments>http://www.worldpharmanews.net/Product/Bristol-Myers_Squibb_Pharma_EEIG_withdraws_its_marketing_authorisation_application_for_DuoCover/</comments>
<pubDate>Thu, 29 May 2008 09:46:03 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Bristol-Myers_Squibb_Pharma_EEIG_withdraws_its_marketing_authorisation_application_for_DuoCover/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has been formally notified by Bristol-Myers Squibb Pharma EEIG of its decision to withdraw its application for a centralised marketing authorisation for the medic<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Sanofi Pharma Bristol-Myers Squibb SNC withdraws its marketing authorisation for DuoPlavin]]></title>
<link>http://www.worldpharmanews.net/Product/Sanofi_Pharma_Bristol-Myers_Squibb_SNC_withdraws_its_marketing_authorisation_for_DuoPlavin/</link>
<comments>http://www.worldpharmanews.net/Product/Sanofi_Pharma_Bristol-Myers_Squibb_SNC_withdraws_its_marketing_authorisation_for_DuoPlavin/</comments>
<pubDate>Thu, 29 May 2008 09:45:52 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Sanofi_Pharma_Bristol-Myers_Squibb_SNC_withdraws_its_marketing_authorisation_for_DuoPlavin/</guid>
<description><![CDATA[The European Medicines Agency (EMEA) has been formally notified by Sanofi Pharma Bristol-Myers Squibb SNC of its decision to withdraw its application for a centralised marketing authorisation for the<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients]]></title>
<link>http://www.worldpharmanews.net/Product/High_Dose_Lipitor_Can_Reduce_the_Risk_of_Cardiovascular_Events_in_Bypass_Surgery_Patients/</link>
<comments>http://www.worldpharmanews.net/Product/High_Dose_Lipitor_Can_Reduce_the_Risk_of_Cardiovascular_Events_in_Bypass_Surgery_Patients/</comments>
<pubDate>Sat, 24 May 2008 11:44:41 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/High_Dose_Lipitor_Can_Reduce_the_Risk_of_Cardiovascular_Events_in_Bypass_Surgery_Patients/</guid>
<description><![CDATA[Pfizer Inc announced that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27 percent in patients with heart <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First pre-pandemic vaccine approved to help protect against pandemic influenza]]></title>
<link>http://www.worldpharmanews.net/Product/First_pre-pandemic_vaccine_approved_to_help_protect_against_pandemic_influenza/</link>
<comments>http://www.worldpharmanews.net/Product/First_pre-pandemic_vaccine_approved_to_help_protect_against_pandemic_influenza/</comments>
<pubDate>Wed, 21 May 2008 01:02:16 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/First_pre-pandemic_vaccine_approved_to_help_protect_against_pandemic_influenza/</guid>
<description><![CDATA[GlaxoSmithKline (GSK plc) announced that the European Commission has granted a marketing authorisation for its H5N1 adjuvanted pre-pandemic vaccine, Prepandrix™, in all 27 EU member states. GSK is th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK gets EU green light for 'bird flu' vaccine - Times Online]]></title>
<link>http://www.worldpharmanews.net/Product/GSK_gets_EU_green_light_for_bird_flu_vaccine_-_Times_Online/</link>
<comments>http://www.worldpharmanews.net/Product/GSK_gets_EU_green_light_for_bird_flu_vaccine_-_Times_Online/</comments>
<pubDate>Tue, 20 May 2008 09:40:03 EEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/GSK_gets_EU_green_light_for_bird_flu_vaccine_-_Times_Online/</guid>
<description><![CDATA[GlaxoSmithKline said this morning that a vaccine that could help prevent an outbreak of the H5N1 'bird flu' virus had been approved by the European Commission. The vaccine, Prepandrix, is the first<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent]]></title>
<link>http://www.worldpharmanews.net/Product/Nexavar_Significantly_Extends_Overall_Survival_in_Liver_Cancer_by_47_percent/</link>
<comments>http://www.worldpharmanews.net/Product/Nexavar_Significantly_Extends_Overall_Survival_in_Liver_Cancer_by_47_percent/</comments>
<pubDate>Sun, 18 May 2008 14:40:38 EEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Nexavar_Significantly_Extends_Overall_Survival_in_Liver_Cancer_by_47_percent/</guid>
<description><![CDATA[Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the A<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
